ACADIA Pharmaceuticals Inc.


Here’s Why ACADIA Pharmaceuticals Inc. (ACAD) Shares Are Diving Today

Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Cowen Dives In on ACADIA Pharmaceuticals Inc. (ACAD) Following Meeting with Management

Cowen analyst Ritu Baral has recently attended a meeting with ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) management to discuss the maturing Nuplazid launch in PDP as well as …

ACADIA Pharmaceuticals Inc. (ACAD) Nuplazid on a Roll, Marvels Cowen

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are shooting up almost 17% with investors clearly paying keen attention to the biotech firm’s Parkinson’s Disease Psychosis …

What Analysts Are Saying About Biotech Stocks Achillion Pharmaceuticals, Inc. And ACADIA Pharmaceuticals Inc.

Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc.

ACADIA Pharmaceuticals Inc. (ACAD) Provides 2Q:17 Update; Shares Spike

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the second quarter ended June 30, 2017.

Analysts Highlight Encouraging Potential in Valeant Pharmaceuticals Intl Inc (VRX), ACADIA Pharmaceuticals Inc. (ACAD), Endo International plc (ENDP)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Endo International plc – Ordinary Shares (NASDAQ:ENDP) each beat expectations on Tuesday as …

ACADIA Pharmaceuticals Inc. (ACAD) Announces Q1:17 Results; Shares Dip

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the first quarter ended March 31, 2017.

Iceberg Ahead With Valeant Pharmaceuticals Intl Inc (VRX) Weak Guidance, ACADIA Pharmaceuticals Inc. (ACAD) Steers Towards Upside

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has Canaccord worried after releasing 2017 financial guidance yesterday morning that came up short of already subdued expectations. …

Piper Jaffary Previews ACADIA Pharmaceuticals Inc.’s (ACAD) Upcoming Earnings

Piper Jaffray analyst Charles Duncan is out with a research note on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), previewing the drug maker’s upcoming earnings announcement, as well as …

Needham Divided On Two Biotech Players: Gilead Sciences, Inc. (GILD), ACADIA Pharmaceuticals Inc. (ACAD)

Needham analyst Alan Carr is out with a mixed research report today on biotech players Gilead Sciences, Inc. (NASDAQ:GILD) and ACADIA Pharmaceuticals Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts